Navigation Links
MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- MicroConstants, Inc., a bioanalytical and pharmacokinetic-specialty Contract Research Organization (CRO) in San Diego, California, announces today that it has successfully completed the installation and qualification of a new Xevo® TQ-S tandem mass spectrometer from Waters Corporation. The unparalleled speed, sensitivity and accuracy of this new LC/MS/MS system will allow MicroConstants to quantify compounds at lower concentrations than previously possible and enable the development of more robust bioanalytical methods for even the most analytically complex compounds.

The Xevo® TQ-S tandem mass spectrometer was released in September of 2010 and this state-of-the-art LC/MS/MS system further increases the high sensitivity provided by the previous model, the Xevo® TQ MS, which MicroConstants acquired last June. The addition of this new system brings MicroConstants equipment count to a total of 16 LC/MS/MS systems at their San Diego bioanalytical laboratory.

When compared to earlier generation mass spectrometer models, MicroConstants experienced a forty fold increase in sensitivity with compounds tested internally in negative electrospray ionization mode. The significant increase in sensitivity can be attributed primarily to the system's new StepWave™ ion-transfer technology. This off-axis design dramatically increases the efficiency of ion transfer from the ion source to the quadrupole MS analyzer while at the same time actively eliminating undesirable neutral contaminants.

"Over the years, MicroConstants has gained a reputation for having the ability to develop bioanalytical methods for complex compounds when others have been unsuccessful in doing so," said David Beyerlein, vice president of global operations at MicroConstants. "This new LC/MS/MS system will allow our innovative method development team to improve methods and speed up method development for analytically complex compounds to help advance our clients' drug development programs."

About MicroConstants, Inc.

MicroConstants is a specialty Contract Research Organization (CRO) in San Diego, California that provides GLP-compliant bioanalytical research services, IND-enabling drug metabolism (DMPK) assays, ELISA immunoassay and pharmacokinetic analysis services to pharmaceutical and biotech companies developing new chemical entities worldwide. They specialize in method development, method validation and sample analysis of small molecules, proteins and peptides using LC/MS/MS, HPLC/UV and ELISA for preclinical and clinical drug development studies. For more information about MicroConstants and the contract research services they provide, please visit http://www.microconstants.com.


'/>"/>
SOURCE MicroConstants, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants Now Offers Nanoparticle Formulation Services
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Following receiving CE Marking in ... s AMAR is a major milestone for the country where the ... ound care market in Israel ... for inclusion in the National Health Basket , Israel ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment ...
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and ... Dry eye market. The research answers the following questions: ... and their clinical attributes? How are they positioned in the Global Dry ...
(Date:2/24/2017)... 2017 The U.S. Food and Drug ... Kit, performed on the Pheno System. This is ... bloodstream infections and provide information about which antibiotics ... sensitivity). The test also reduces the amount of ... which can guide antibiotic treatment recommendations more quickly. ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Rosica Communications, a national PR ... media relations, social media, content marketing and SEO, is now offering direct, social ... intuitive marketing automation platform. , Rosica will now offer the platform to its ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
Breaking Medicine News(10 mins):